COMP <GO>
ATRC vs LLY // 10Y YIELD & FRED MACRO BETA
AtriCure Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ATRC 1
— LLY 10
■ METRIC PARITY
LAST: $61.25 (-1.97%) • MKT CAP: $3.18B
macro-sensitivity
—
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.29T
macro-sensitivity
0.51
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ATRC VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ATRC | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 75.00% | 83.64% | -8.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -1.90% | 32.36% | -34.26 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.52% | 2.30% | -0.78 | LLY | /fcf-yield <GO> |
| Operating Margin | -1.80% | 40.21% | -42.01 | LLY | /operating-margins <GO> |
| Net Profit Margin | -2.10% | 31.90% | -34.00 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 14.90% | 45.51% | -30.61 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.08 | 9.29 | +2.79 | ATRC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.0 | 66.6 | -0.60 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 30.6x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.18B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ATRC REV | LLY REV | ATRC GROSS % | LLY GROSS % | ATRC FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $534.5M | $65.18B | 75.0% | 83.0% | $48.3M | $16.81B |
| FY 2024 | $465.3M | $45.04B | 74.7% | 81.3% | $745.0K | $8.82B |
| FY 2023 | $399.2M | $34.12B | — | 79.3% | $4.5M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ATRC // BETA —
LLY // BETA 0.51